Wave Life Sciences (WVE) fell ~57% in the premarket on Thursday as Wall Street reacted to interim data from an early-stage trial for WVE-007, its RNA-based obesity medicine. Citing six-month follow-up ...

Wave Life Sciences stock crashed Thursday after the company's much-hyped "body composition" drug led to just 1% weight loss ...

Wave Life Sciences shares plunged over 55% on Thursday after a higher dose of its experimental ​obesity drug failed to show a ...

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...

Preclinical findings show cytisinicline's minimal 5-HT3 serotonin receptor binding offers insight into observed low nausea ...

The first industry-designed accreditation dedicated specifically to the safe, compliant, and human-supervised use of AI ...

Wave Life Sciences (WVE) stock plunged 30% after INLIGHT Phase 1 obesity trial data revealed modest results, sparking ...

Loomis Sayles, an investment management company, released its fourth-quarter 2025 investor letter for “Small Cap Growth Fund” ...

ARDMORE, PA, UNITED STATES, March 24, 2026 /EINPresswire.com/ — Blue Mountain, a leading provider of enterprise asset management (EAM), calibration, maintenance, and validation solutions for regulated ...

Stewart reaffirmed the company's near-term priority as "receiving NDA approval and successfully launching cytisinicline for smoking cessation," with a planned commercial launch in the first half of ...

At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted ...

Alphabet's life sciences business Verily is restructuring and raising money as a new corporate entity. Verily announced that ...